Radiopharmaceuticals in Nuclear Medicine Market Poised to Witness High Growth Owing to Increasing Prevalence of Chronic Diseases
Radiopharmaceuticals in Nuclear Medicine Market Radiopharmaceuticals in nuclear medicine are radioactive drugs that emit radiation used for diagnostic imaging and therapeutic purposes. Some of the commonly used radiopharmaceuticals include Tc-99m, F-18, I-123/I-131, and Ga-67. They play a vital role in nuclear medicine procedures like positron emission tomography (PET), single-photon emission computed tomography (SPECT), and therapeutic radiopharmaceuticals. The increasing prevalence of chronic diseases like cancer, heart diseases is driving the demand for effective diagnostic and therapeutic procedures. The global radiopharmaceuticals in nuclear medicine market is estimated to be valued at US$ 9115.96 Mn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period 2024 to 2031. Key Takeaways Key players: Key players operating in the radiopharmaceuticals in nuclear medicine market are Progenics Pharmaceuticals, Inc., NorthStar Medical Radioisotopes LLC, Curium Ph...